SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
JBT Marel Corporation (JBT) , forward earnings yield 4.81%. PEG 0.87 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (50/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 20.8
- PEG Ratio 0.87 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Analyst consensus target $128.00 (+2.1% upside) — modest upside expected.
Overall SharesGrow Score: 52/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
50/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — JBT
Valuation Multiples
P/E (TTM)0.0
Forward P/E20.8
PEG Ratio0.87
Forward PEG0.87
P/B Ratio0.00
P/S Ratio1.72
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.96
Forward EPS (Est.)$6.03
Book Value / Share$0.00
Revenue / Share$73.04
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield4.81%
Dividend Yield0.00%
Analyst Target$128.00 (+2.1%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$2.27 |
$1.35B |
$67.6M |
5% |
| 2017 |
$2.53 |
$1.64B |
$80.5M |
4.9% |
| 2018 |
$3.23 |
$1.92B |
$104.1M |
5.4% |
| 2019 |
$4.03 |
$1.95B |
$129M |
6.6% |
| 2020 |
$3.39 |
$1.73B |
$108.8M |
6.3% |
| 2021 |
$3.69 |
$1.87B |
$119.1M |
6.4% |
| 2022 |
$4.28 |
$2.17B |
$137.4M |
6.3% |
| 2023 |
$18.15 |
$1.66B |
$582.6M |
35% |
| 2024 |
$2.66 |
$1.72B |
$85.4M |
5% |
| 2025 |
$-0.96 |
$3.8B |
$-50.5M |
-1.3% |
